Totem ( the startup behind the first widely adopted peer-to-peer navigation device designed to work entirely without cellular service, today announced Version 4.1 of the Totem Compass and a newly ...

Don't underestimate Samsung's handy side-swipe menu ...

Thirty-five-year-old Amy Drew of Bennington writes under the pen name of Elizabeth DeCicco. She writes when the mood and the spirit move her, and whenever she can find ...

This is an ambient version of how to do that, where I’m just dropping explosions in the music in a more cerebral, landscape ...

The world of cryptocurrency is expanding at an unprecedented pace. What once was a niche market primarily discussed in online forums and niche communities has now become a global financial phenomenon, ...

Because in today’s world, giving the thumb away is no longer a sign of obedience or respect. It’s about giving away your most significant advantage—in addition to the biometric key to your phone, your ...

Misery is a strange and tough game. It has some mechanics and systems that it shares with other survival titles, but there are a few unique to Misery, including its atmosphere and presentation. You ...

Furthering your education locally is easy, with a wide range of training opportunities offered by schools and organisations island-wide.

Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaining a ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Compass Pathways on ...

Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depression (TRD) ...

Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the British biotech’s share price up 30% and teeing up talks about filing for ...